A novel companion diagnostic assay for BRAF V600E/K detection in melanoma: High clinical concordance of patient outcomes for trametinib and debrafenib treatment

被引：0
|
作者：
O'Donnell, L. [1 ]
Sweet, W. [1 ]
Lu, X. [1 ]
Meynier, F. [2 ]
Derome, A. [3 ]
Ganee, L. [3 ]
Poyet-Gelas, F. [3 ]
Martin, A.
Casey, M.
Kertesz, N. [4 ]
机构：
[1] BioMerieux Inc, Clin Affairs, Durham, NC USA
[2] BioMerieux Inc, BioMath, Grenoble, France
[3] BioMerieux Inc, R&D, Grenoble, France
[4] Response Genet Inc, Pharmaceut Liaison, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页码：S862 / S862
页数：1
相关论文
共 50 条
  • [41] Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma
    Halait, Harkanwal
    DeMartin, Kelli
    Shah, Sweta
    Soviero, Stephen
    Langland, Rachel
    Cheng, Suzanne
    Hillman, Grantland
    Wu, Lin
    Lawrence, H. Jeffrey
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2012, 21 (01) : 1 - 8
  • [42] Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
    Long, G. V.
    Flaherty, K. T.
    Stroyakovskiy, D.
    Gogas, H.
    Levchenko, E.
    de Braud, F.
    Larkin, J.
    Garbe, C.
    Jouary, T.
    Hauschild, A.
    Chiarion-Sileni, V.
    Lebbe, C.
    Mandala, M.
    Millward, M.
    Arance, A.
    Bondarenko, I.
    Haanen, J. B. A. G.
    Hansson, J.
    Utikal, J.
    Ferraresi, V.
    Mohr, P.
    Probachai, V.
    Schadendorf, D.
    Nathan, P.
    Robert, C.
    Ribas, A.
    Davies, M. A.
    Lane, S. R.
    Legos, J. J.
    Mookerjee, B.
    Grob, J. -J.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1631 - 1639
  • [43] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
    Igor Puzanov
    Journal of Translational Medicine, 13 (Suppl 1)
  • [44] Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report
    Inoue, Takako
    Kunimasa, Kei
    Tamiya, Motohiro
    Kawamura, Takahisa
    Minami, Toshiyuki
    Nishino, Kazumi
    THORACIC CANCER, 2024, 15 (11) : 929 - 933
  • [45] Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases
    Kawaguchi, Yuki
    Watanabe, Yuko
    Miyakita, Yasuji
    Ohno, Makoto
    Ogawa, Chitose
    Takahashi, Masamichi
    Yanagisawa, Shunsuke
    Mukai, Takayuki
    Igaki, Hiroshi
    Sugino, Hirokazu
    Yoshida, Akihiko
    Narita, Yoshitaka
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (03) : 256 - 262
  • [46] Clinical and histologic signs of regression two months after initiation of treatment with dabrafenib and trametinib in a case of stage IIIc BRAF V600E-positive scalp melanoma
    Wei, Erin
    Cordero, Roberto Ruiz
    Zhou, Xiaolong
    Feun, Lynn
    Thomas, Giovanna
    Cho-Vega, Jeong Hee
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB165 - AB165
  • [47] Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma
    Meletath, Silviya K.
    Pavlick, Dean
    Brennan, Tim
    Hamilton, Roy
    Chmielecki, Juliann
    Elvin, Julia A.
    Palma, Norma
    Ross, Jeffrey S.
    Miller, Vincent A.
    Stephens, Philip J.
    Snipes, George
    Rajaram, Veena
    Ali, Siraj M.
    Melguizo-Gavilanes, Isaac
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (11): : 1345 - 1350
  • [48] Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion
    Kocsis, Judit
    Arokszallasi, Anita
    Andras, Csilla
    Balogh, Ingrid
    Beres, Edit
    Deri, Julia
    Petak, Istvan
    Janvary, Levente
    Horvath, Zsolt
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (02) : E32 - E38
  • [49] Requisite Analytic and Diagnostic Performance Characteristics for the Clinical Detection of BRAF V600E in Hairy Cell Leukemia: A Comparison of 2 Allele-specific PCR Assays
    Brown, Noah A.
    Weigelin, Helmut C.
    Bailey, Nathanael
    Laliberte, Julie
    Elenitoba-Johnson, Kojo S. J.
    Lim, Megan S.
    Betz, Bryan L.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (08) : 590 - 600
  • [50] Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay
    Vallee, Audrey
    Denis-Musquer, Marie
    Herbreteau, Guillaume
    Theoleyre, Sandrine
    Bossard, Celine
    Denis, Marc G.
    PLOS ONE, 2019, 14 (08):
12345